Genentech registers Phase I trial of RO7890597 in healthy volunteers
A new early-stage safety and pharmacokinetics study joins an existing Ohio State-sponsored observational trial in relapsed small-cell lung cancer.
This week's registry activity includes a new Genentech-sponsored Phase I study plus an update on a previously reported observational trial in which Genentech is a collaborator.
- Genentech, Inc. registered a Phase I study of RO7890597 (NCT07797478) in healthy adult volunteers, recruiting participants ages 18 to 65. The study has an estimated enrollment of 139 participants.1 The trial is recruiting at one site in the United States, ICON (LPRA) in Lenexa, Kansas.1 Its primary outcome is the incidence and severity of adverse events, assessed up to approximately 12 weeks.1
- Ohio State University Comprehensive Cancer Center's observational study "Prospective Multiomic Analysis in Small-Cell Lung Cancer" (NCT07795411) remains recruiting, with Genentech, Inc. listed as a collaborator. The study is recruiting at one site in Columbus, Ohio.2 Its primary objective is to assess the feasibility of obtaining paired tumor samples and serial blood collection in relapsed ES-SCLC patients.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.